Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
Sep 12, 2017 Celldex Announces Departure of Chief Medical Officer
Aug 23, 2017 Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Aug 8, 2017 Form 10-Q View HTML View PDF 815.5 KB Add to Briefcase
Mar 14, 2017 Form 10-K View HTML View PDF 809.4 KB Add to Briefcase
Add to Briefcase = add file to Briefcase